Clinical potential of sodium-calcium exchanger inhibitors as antiarrhythmic agents

Steven M Pogwizd1

  • 1Department of Medicine, University of Illinois at Chicago, 8430 South Wood Street, Chicago, IL 60612, USA. spogwizd@uic.edu

Drugs
|February 26, 2003
PubMed

Insights

Inhibiting the sodium-calcium exchanger (NaCaX) may prevent arrhythmias in heart failure and ischemia. Developing specific NaCaX inhibitors is crucial for this antiarrhythmic approach.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • The sodium-calcium exchanger (NaCaX) is vital for myocyte calcium homeostasis.
  • Dysfunctional NaCaX contributes to arrhythmias in heart failure and myocardial ischemia/reperfusion.
  • NaCaX can operate in forward (calcium extrusion) or reverse (calcium influx) modes.

Purpose of the Study:

  • To explore the antiarrhythmic potential of NaCaX inhibition in heart failure and ischemia/reperfusion.
  • To discuss the challenges in developing specific NaCaX inhibitors.
  • To review the role of NaCaX in myocyte calcium and sodium handling.

Main Methods:

  • Review of existing literature on NaCaX function in cardiovascular pathophysiology.
  • Analysis of the mechanisms underlying NaCaX-mediated arrhythmogenesis.
  • Discussion of the limitations of current non-specific NaCaX inhibitors.

Main Results:

  • Upregulated NaCaX in heart failure reduces SR calcium load and promotes arrhythmogenic transient inward current (I(ti)).
  • Increased intracellular sodium in ischemia/reperfusion activates NaCaX, leading to calcium overload and arrhythmias.
  • Lack of specific NaCaX inhibitors hinders therapeutic assessment.

Conclusions:

  • NaCaX inhibition presents a potential antiarrhythmic strategy for heart failure and ischemia/reperfusion.
  • Targeting specific NaCaX modes (forward/reverse) may offer therapeutic benefits.
  • Further research into NaCaX function and development of specific inhibitors are essential for clinical application.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...